Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW® 2024
“At Exact Sciences, we know colorectal cancer screening must be able to find and also help prevent the disease to positively impact patient outcomes, which is how the Cologuard test was designed,” said
The following abstracts from
Session Type:
Session Title: Colorectal Cancer Screening and Surveillance: Cohort, Clinical Outcomes & Comparative Effectiveness Studies including Trials
Session Date & Time:
Presentation Title: Comparison Of Efficient Frontier Strategies For Guideline-endorsed Vs Non-endorsed Colorectal Cancer Screening Tests
Session Type:
Session Title: Colorectal Cancer Screening and Surveillance: Cohort, Clinical Outcomes & Comparative Effectiveness Studies including Trials
Session Date & Time:
Presentation Title: Comparison Of Efficient Frontier Strategies For Stool-based Colorectal Cancer Screening Tests
Session Type:
Session Title: Colorectal Cancer Screening and Surveillance: Cohort, Clinical Outcomes & Comparative Effectiveness Studies including Trials
Session Date & Time:
Presentation Title: Estimated Average-risk Colorectal Cancer Screening-eligible Population In The
Session Type:
Session Title: Colorectal Cancer Screening and Surveillance: Cohort, Clinical Outcomes & Comparative Effectiveness Studies including Trials
Session Date & Time:
Presentation Title: Eliminating The Colonoscopy Backlog With Stool-based Colorectal Cancer Screening Options
Session Type:
Session Title: Cancer, Early Detection, Biomarkers for Diagnosis, Treatment and Prognosis of GI Cancers
Session Date & Time:
Presentation Title: Fecal Immunochemical Test (Fit) Performance Characteristics In Males And Females: Should The Threshold Vary?
Session Type:
Session Title: Health Disparities in Patients with GI Disease
Session Date & Time:
Presentation Title: Impact Of Racial Disparities In The Quality Of Colonoscopy Screening On Colorectal Cancer Incidence And Mortality: A Simulation Modeling Analysis
About Cologuard
Results from Exact Sciences’ prospective, 90-site, point-in-time, 10,000-patient pivotal trial, DeeP-C, were published in the
The Cologuard test result should be interpreted with caution. A positive test result does not confirm the presence of cancer. Patients with a positive test result should be referred for colonoscopy. A negative test result does not confirm the absence of cancer. Patients with a negative test result should discuss with their doctor when they need to be tested again. Medicare and most major insurers cover the Cologuard test. For more information about the Cologuard test, visit cologuard.com. Rx only.
About
A leading provider of cancer screening and diagnostic tests,
NOTE:
About Digestive Disease Week
Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the
Forward-Looking Statements
This news release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding the development and commercialization of the next-generation Cologuard test; the performance characteristics of next-generation Cologuard in a commercial setting; and the timing and anticipated results of additional analysis of the BLUE-C data and FDA submission. Risks and uncertainties that may affect our forward-looking statements are described in the Risk Factors sections of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the
References
- Siegel RL, et al. 2023. CA Cancer J Clin. 2023;73(3):233-254.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240507199503/en/
Media (
+1 608-690-0383
lidickinson@exactsciences.com
Investors:
+1 608 535-8659
investorrelations@exactsciences.com
Source: